Key facts
- R3 Bio (Drug Delivery)’s last known valuation is $46.4M (Jul 2025).
- It has raised $9.4M; the latest was Seed Round ($9.4M) in Jul 2025.
- Notable investors include Timothy Draper, Immortal Dragons, LongGame.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for R3 Bio (Drug Delivery)
- ·The full record, as it builds
Funding rounds
No funding rounds for R3 Bio (Drug Delivery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About R3 Bio (Drug Delivery)
Developer of cell-based research platforms designed to build human-relevant in vitro biological models that support more predictive preclinical research and reduce reliance on animal studies. The company's platform combines cellular reprogramming workflows, stem-cell-derived systems, and integrated biological signaling measurements, enabling pharmaceutical and biotechnology researchers to generate more informative preclinical data and evaluate mechanistic biology in controlled, ethically preferable research settings.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Website
- r3-bio.com/
- Ownership
- Privately Held (backing)
R3 Bio (Drug Delivery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in R3 Bio (Drug Delivery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on R3 Bio (Drug Delivery) in its N-PORT filings yet. We sweep new filings monthly.